| Chemical Information | |
| Antiviral agent ID | DrugRepV_3964 | |
| Antiviral agent name | 12N-3,4-dichlorobenzoyl aloperine | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Ebola virus (EBOV) NA NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | HEK-293T
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 48 hours
| |
|
Secondary Indication (Drug concentration) | 49 μM
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
|
Secondary Indication (Cytotoxicity) | 200 μM | |
|
Reference | Zhang X, Liu Q, Zhang N, Li QQ, Liu ZD, Li YH, Gao LM, Wang YC, Deng HB, Song DQ..Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage..Eur J Med Chem. 2018 Apr 10;149:45-55. doi: 10.1016/j.ejmech.2018.02.061. PMID:29494844
|  |
|
Comment | Aloperine is a chinese natural product with a unique endocyclic skeleton, that demonstrate a good anti-EBOV activity with a half maximal effective concentration (EC50) value of 12.4 mM and a selective index (SI) value of over 16.1.
| |